{"id":"NCT00421928","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","briefTitle":"Tapentadol (CG5503)","officialTitle":"A Randomized Double-Blind, Placebo- and Active-Control, Parallel-arm, Phase III Trial With Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Extended-Release (ER) in Patients With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-01","primaryCompletion":"2008-07","completion":"2008-12","firstPosted":"2007-01-15","resultsPosted":"2010-04-23","lastUpdate":"2012-04-18"},"enrollment":1030,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Osteoarthritis, Knee","Pain"],"interventions":[{"type":"DRUG","name":"oxycodone","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"tapentadol (CG5503)","otherNames":[]}],"arms":[{"label":"001","type":"EXPERIMENTAL"},{"label":"002","type":"ACTIVE_COMPARATOR"},{"label":"003","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this trial is to evaluate the effectiveness (level of pain control) and safety of orally administered tapentadol (CG5503) Extended Release (ER) (base) at doses of 100-250 mg twice daily in patients with moderate to severe chronic pain due to osteoarthritis of the knee, in comparison with placebo and Oxycodone Controlled Release (CR).","primaryOutcome":{"measure":"Change From Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12.","timeFrame":"Baseline and 12 weeks (Primary endpoint is the average pain intensity score during the last week of the maintenance period).","effectByArm":[{"arm":"Tapentadol (CG5503)","deltaMin":-3,"sd":2.39},{"arm":"Oxycodone","deltaMin":-2.6,"sd":2.38},{"arm":"Placebo","deltaMin":-2.2,"sd":2.54}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.05"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["24985410","24916058","24353047","23709304","23340531"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=69&filename=CR013402_CSR.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":344},"commonTop":["Nausea","Constipation","Headache","Dizziness","Somnolence"]}}